Publications

Scientific publications

Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels imiuring lenalidomide treatment in Low-and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion, Eur J. Haematol, 2010; 85:231-5.   

http://ncbi.nlm.nih.gov/pubmed/20491881

Oliva EN, Nobile F, Alimena G, et al. Darbepoetin For The Treatment Of Anemia Of Myelodysplastic Syndromes: Efficacy And Quality Of Life. Leukemia and Lymphoma, 2010; 51(6):1007-14.

http://www.ncbi.nlm.nih.gov/pubmed/20367566 

Breccia M, Cannella L, Latagliata R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of short course of lenalidomide due to severe skin rash in a 5q syndrome patient. J Clin Oncol, 2011; May 10;29(14): e 402-3.

http://ncbi.nlm.nih.gov/pubmed/21357784

Breccia M, Cannella L, Latagliata R, et al. Sudden acute leukemia transformation in a MDS patient with del (5q) in complete cytogenetic remission after lenalidomide. Leuk Res., 2011; 35, 690.

http://ncbi.nlm.nih.gov/pubmed/21232796

Cannella L, Latagliata R, Breccia M, et al. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, 2012;  Feb; 91 (2):309-10.

https://www.ncbi.nlm.nih.gov/pubmed/21625998

Oliva EN, Cuzzola M, Poloni A, et al. Biological activity of lenalidomide in myelodysplastic sindromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol., 2013;  Jan;92(1):25-32.

https://www.ncbi.nlm.nih.gov/pubmed/22983750

Oliva EN, Latagliata R, Laganà C, et al. Lenalidomide in Low-and intermediate-1 IPSS risk myelodysplastic sindromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and efficacy. Leuk Linphoma., 2013;  Nov;54(11):2458-65.

https://www.ncbi.nlm.nih.gov/pubmed/2343272

Oliva EN, Lauseker M, Aloe Spiriti MA, at al. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med.2015; Dec; 4(12):1789-97.

https://www.ncbi.nlm.nih.gov/pubmed/26376955

Oliva EN, Alati C, Santini V, et al.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;  Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1.

https://www.ncbi.nlm.nih.gov/pubmed/28162984

Congress presentations

Oliva EN, Nobile F., Alimena G., et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;  May; 96(5):696-702

https://www.ncbi.nlm.nih.gov/pubmed/21330327

Oliva EN,  Alati C,  Salutari P, at al. Azacitidine As Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia Significantly Prolongs Disease-Free Survival: Interim Results from a Prospective, Randomized, Open-Label, Phase III Multicenter Trial. Blood 2014;  124:2299; by The American Society of Hematology.

http://www.bloodjournal.org/content/124/21/2299

Oliva EN, Santini V, Alati C, at al. Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial.  Blood, 2015; 126:91  by The American Society of Hematology

http://www.bloodjournal.org/content/126/23/91

Oliva EN, Salutari P, Candoni A, et al. Quality of life in elderly patients with acute myeloid leukemia undergoing induction chemotherapy. Blood 2015; 126:2120. by The American Society of Hematology

http://www.bloodjournal.org/content/126/23/2120

Cuzzola M, Alati C, Di Bartolomeo P, et al. Biological Markers of relapse in elderly patients with AML in CR after induction consolidation chemotherapy and maintenance with 5-azocitidine. 2016; EHA Learning Center.

https://learningcenter.ehaweb.org/eha/2016/21st/132455

Oliva EN, Zappavigna S, Santacaterina I, et al. Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies . Oral and Poster Abstracts, Session: 102. Regulation of Iron Metabolism: Poster III, by the American Society of Hematology 2017

https://ash.confex.com/ash/2017/webprogram/Paper108243.html